Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jul 1:13:1756286420932035.
doi: 10.1177/1756286420932035. eCollection 2020.

Eculizumab as a promising treatment in thymoma-associated myasthenia gravis

Valentina Vélez-Santamaría  1 , Velina Nedkova  2 , Laura Díez  2 , Christian Homedes  2 , M Antonia Alberti  2 , Carlos Casasnovas  3
Affiliations
Case Reports

Eculizumab as a promising treatment in thymoma-associated myasthenia gravis

Valentina Vélez-Santamaría et al. Ther Adv Neurol Disord. .

Abstract

Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting.

Keywords: case report; complement inhibitor; eculizumab; myasthenia gravis; refractory; thymoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
QMG (blue line) and MG-ADL (red line) scores under the different immunosuppressant treatments. MG-ADL, myasthenia gravis activities of daily living; QMG, quantitative myasthenia gravis.
See this image and copyright information in PMC

References

    1. Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res 2016; 5: 1513. - PMC - PubMed
    1. Cetin H, Vincent A. Pathogenic mechanisms and clinical correlations in autoimmune myasthenic syndromes. Semin Neurol 2018; 38: 344–354. - PubMed
    1. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015; 14: 1023–1036. - PubMed
    1. Maggi L, Andreetta F, Cavalcante P, et al. Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. J Neuroimmunol 2008; 201–202: 237–244. - PubMed
    1. Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 2013; 86: 255–260. - PMC - PubMed

Publication types